Lv3
320 积分 2022-04-01 加入
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
2个月前
已完结
Efficacy of Concurrent Chemoradiotherapy With S-1 vs Radiotherapy Alone for Older Patients With Esophageal Cancer
2个月前
已完结
Effectiveness of S-1–Based Chemoradiotherapy in Patients 70 Years and Older With Esophageal Squamous Cell Carcinoma
2个月前
已完结
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
7个月前
已完结
Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC
10个月前
已完结
Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2
10个月前
已完结
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
10个月前
已完结
Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non–small-cell Lung Cancer: LAURA Trial in Progress
10个月前
已完结
Immune‐related adverse events after immune check point inhibitors: Understanding the intersection with autoimmunity
11个月前
已完结
Clonally expanded, thyrotoxic effector CD8 + T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis
11个月前
已完结
皖公网安备34019202002308
